Predict your next investment

Corporation
HEALTHCARE | Biotechnology
inva.com

See what CB Insights has to offer

Founded Year

1996

Stage

IPO | IPO

Total Raised

$159.33M

Date of IPO

10/5/2004

Market Cap

1.18B

Stock Price

16.92

About Innoviva

Innoviva (NASDAQ: INVA) specializes in royalty management. Innoviva is a company with a portfolio of royalties that include respiratory assets.

Innoviva Headquarter Location

1350 Old Bayshore Highway Suite 400

Burlingame, California, 94010,

United States

650-238-9600

Latest Innoviva News

Theravance Biopharma to Participate in an Upcoming Investor Conference

Nov 18, 2021

News provided by Share this article Share this article DUBLIN, Nov. 18, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ), a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines, will participate in a fireside chat as follows:  Evercore ISI 4th Annual HEALTHCONx Virtual Conference on Tuesday, November 30, at 11:20 am ET (8:20 am PT/4:20 pm GMT) Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Presentations and Events. Replay of the webcast will be archived on the Company's website for 30 days. About Theravance Biopharma Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines. Its core purpose is to create medicines that help improve the lives of patients suffering from respiratory illness. In pursuit of its purpose, Theravance Biopharma leverages decades of respiratory expertise to discover and develop transformational medicines that make a difference. These efforts have led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its respiratory pipeline of internally discovered programs is targeted to address significant patient respiratory needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit  www.theravance.com . THERAVANCE BIOPHARMA®, THERAVANCE®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the US and certain other countries). YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris Company. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners. Contact Information:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Innoviva Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Innoviva Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.